Developmental Neurotoxic Effects of Percutaneous Drug Delivery: Behavior and Neurochemical Studies in C57BL/6 Mice.

Dermatosis often as a chronic disease requires effective long-term treatment; a comprehensive evaluation of mental health of dermatology drug does not receive enough attention. An interaction between dermatology and psychiatry has been increasingly described. Substantial evidence has accumulated tha...

Full description

Bibliographic Details
Main Authors: Huali Wu, Junyi Feng, Wenting Lv, Qiaoling Huang, Mengsi Fu, Minxuan Cai, Qiangqiang He, Jing Shang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5015905?pdf=render
id doaj-1291b5196ef648639894a695f2da3566
record_format Article
spelling doaj-1291b5196ef648639894a695f2da35662020-11-25T00:05:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01119e016257010.1371/journal.pone.0162570Developmental Neurotoxic Effects of Percutaneous Drug Delivery: Behavior and Neurochemical Studies in C57BL/6 Mice.Huali WuJunyi FengWenting LvQiaoling HuangMengsi FuMinxuan CaiQiangqiang HeJing ShangDermatosis often as a chronic disease requires effective long-term treatment; a comprehensive evaluation of mental health of dermatology drug does not receive enough attention. An interaction between dermatology and psychiatry has been increasingly described. Substantial evidence has accumulated that psychological stress can be associated with pigmentation, endocrine and immune systems in skin to create the optimal responses against pathogens and other physicochemical stressors to maintain or restore internal homeostasis. Additionally, given the common ectodermal origin shared by the brain and skin, we are interested in assessing how disruption of skin systems (pigmentary, endocrine and immune systems) may play a key role in brain functions. Thus, we selected three drugs (hydroquinone, isotretinoin, tacrolimus) with percutaneous excessive delivery to respectively intervene in these systems and then evaluate the potential neurotoxic effects. Firstly, C57BL/6 mice were administrated a dermal dose of hydroquinone cream, isotretinoin gel or tacrolimus ointment (2%, 0.05%, 0.1%, respectively, 5 times of the clinical dose). Behavioral testing was performed and levels of proteins were measured in the hippocampus. It was found that mice treated with isotretinoin or tacrolimus, presented a lower activity in open-field test and obvious depressive-like behavior in tail suspension test. Besides, they damaged cytoarchitecture, reduced the level of 5-HT-5-HT1A/1B system and increased the expression of apoptosis-related proteins in the hippocampus. To enable sensitive monitoring the dose-response characteristics of the consecutive neurobehavioral disorders, mice received gradient concentrations of hydroquinone (2%, 4%, 6%). Subsequently, hydroquinone induced behavioral disorders and hippocampal dysfunction in a dose-dependent response. When doses were high as 6% which was 3 times higher than 2% dose, then 100% of mice exhibited depressive-like behavior. Certainly, 6% hydroquinone exposure elicited the most serious impairment of hippocampal structure and survival. The fact that higher doses of hydroquinone are associated with a greater risk of depression is further indication that hydroquinone is responsible for the development of depression. These above data demonstrated that chronic administration of different dermatology drugs contributed into common mental distress. This surprising discovery of chemical stressors stimulating the hippocampal dysfunction, paves the way for exciting areas of study on the cross-talk between the skin and the brain, as well as is suggesting how to develop effective and safe usage of dermatological drugs in daily practice.http://europepmc.org/articles/PMC5015905?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Huali Wu
Junyi Feng
Wenting Lv
Qiaoling Huang
Mengsi Fu
Minxuan Cai
Qiangqiang He
Jing Shang
spellingShingle Huali Wu
Junyi Feng
Wenting Lv
Qiaoling Huang
Mengsi Fu
Minxuan Cai
Qiangqiang He
Jing Shang
Developmental Neurotoxic Effects of Percutaneous Drug Delivery: Behavior and Neurochemical Studies in C57BL/6 Mice.
PLoS ONE
author_facet Huali Wu
Junyi Feng
Wenting Lv
Qiaoling Huang
Mengsi Fu
Minxuan Cai
Qiangqiang He
Jing Shang
author_sort Huali Wu
title Developmental Neurotoxic Effects of Percutaneous Drug Delivery: Behavior and Neurochemical Studies in C57BL/6 Mice.
title_short Developmental Neurotoxic Effects of Percutaneous Drug Delivery: Behavior and Neurochemical Studies in C57BL/6 Mice.
title_full Developmental Neurotoxic Effects of Percutaneous Drug Delivery: Behavior and Neurochemical Studies in C57BL/6 Mice.
title_fullStr Developmental Neurotoxic Effects of Percutaneous Drug Delivery: Behavior and Neurochemical Studies in C57BL/6 Mice.
title_full_unstemmed Developmental Neurotoxic Effects of Percutaneous Drug Delivery: Behavior and Neurochemical Studies in C57BL/6 Mice.
title_sort developmental neurotoxic effects of percutaneous drug delivery: behavior and neurochemical studies in c57bl/6 mice.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2016-01-01
description Dermatosis often as a chronic disease requires effective long-term treatment; a comprehensive evaluation of mental health of dermatology drug does not receive enough attention. An interaction between dermatology and psychiatry has been increasingly described. Substantial evidence has accumulated that psychological stress can be associated with pigmentation, endocrine and immune systems in skin to create the optimal responses against pathogens and other physicochemical stressors to maintain or restore internal homeostasis. Additionally, given the common ectodermal origin shared by the brain and skin, we are interested in assessing how disruption of skin systems (pigmentary, endocrine and immune systems) may play a key role in brain functions. Thus, we selected three drugs (hydroquinone, isotretinoin, tacrolimus) with percutaneous excessive delivery to respectively intervene in these systems and then evaluate the potential neurotoxic effects. Firstly, C57BL/6 mice were administrated a dermal dose of hydroquinone cream, isotretinoin gel or tacrolimus ointment (2%, 0.05%, 0.1%, respectively, 5 times of the clinical dose). Behavioral testing was performed and levels of proteins were measured in the hippocampus. It was found that mice treated with isotretinoin or tacrolimus, presented a lower activity in open-field test and obvious depressive-like behavior in tail suspension test. Besides, they damaged cytoarchitecture, reduced the level of 5-HT-5-HT1A/1B system and increased the expression of apoptosis-related proteins in the hippocampus. To enable sensitive monitoring the dose-response characteristics of the consecutive neurobehavioral disorders, mice received gradient concentrations of hydroquinone (2%, 4%, 6%). Subsequently, hydroquinone induced behavioral disorders and hippocampal dysfunction in a dose-dependent response. When doses were high as 6% which was 3 times higher than 2% dose, then 100% of mice exhibited depressive-like behavior. Certainly, 6% hydroquinone exposure elicited the most serious impairment of hippocampal structure and survival. The fact that higher doses of hydroquinone are associated with a greater risk of depression is further indication that hydroquinone is responsible for the development of depression. These above data demonstrated that chronic administration of different dermatology drugs contributed into common mental distress. This surprising discovery of chemical stressors stimulating the hippocampal dysfunction, paves the way for exciting areas of study on the cross-talk between the skin and the brain, as well as is suggesting how to develop effective and safe usage of dermatological drugs in daily practice.
url http://europepmc.org/articles/PMC5015905?pdf=render
work_keys_str_mv AT hualiwu developmentalneurotoxiceffectsofpercutaneousdrugdeliverybehaviorandneurochemicalstudiesinc57bl6mice
AT junyifeng developmentalneurotoxiceffectsofpercutaneousdrugdeliverybehaviorandneurochemicalstudiesinc57bl6mice
AT wentinglv developmentalneurotoxiceffectsofpercutaneousdrugdeliverybehaviorandneurochemicalstudiesinc57bl6mice
AT qiaolinghuang developmentalneurotoxiceffectsofpercutaneousdrugdeliverybehaviorandneurochemicalstudiesinc57bl6mice
AT mengsifu developmentalneurotoxiceffectsofpercutaneousdrugdeliverybehaviorandneurochemicalstudiesinc57bl6mice
AT minxuancai developmentalneurotoxiceffectsofpercutaneousdrugdeliverybehaviorandneurochemicalstudiesinc57bl6mice
AT qiangqianghe developmentalneurotoxiceffectsofpercutaneousdrugdeliverybehaviorandneurochemicalstudiesinc57bl6mice
AT jingshang developmentalneurotoxiceffectsofpercutaneousdrugdeliverybehaviorandneurochemicalstudiesinc57bl6mice
_version_ 1725423405960790016